Fig. 1From: Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial28-day survival dichotomised by baseline plasma IL-18. Kaplan–Meier curve of survival from enrolment to day 28. Survival was higher in patients with low plasma IL-18 at baseline (HR 1.89 [1.30–2.73]; log-rank test p = 0.001)Back to article page